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Oncolytic Virotherapy 
 
Viruses are fascinating infectious agents; they have biochemical structures and employ 
metabolic processes solely for the purposes of entering and replicating within host cells. 
Their genomes are diverse and subject to variability within species, but they are relatively 
short in length. For example in the small rhinoviruses, the genome is single stranded positive 
sense RNA and 7,500 -8,500 base pairs long. In the rather larger poxviruses, the genetic 
material is ds DNA and 130-375, 000 base pairs in length. Even in the recently discovered 
giant viruses of amoebae the ds DNA genome is only ~ 370,000 base pairs in length. By 
comparison, the genome of the well-studied bacterium Escherichia coli is 4.6 million base 
pairs. Therefore many viral genomes have been sequenced, allowing the gene products to be 
analysed, in order to identify which are important for pathogenicity and which are essential 
for replication. Interactions between viral glycoproteins and host cell surface proteins are 
very specific, meaning that attachment and entry is usually restricted to certain cell types. For 
example, the haemagglutinin and neuraminidase of influenza virus are designed to bind to 
respiratory epithelial cells. This knowledge about viral genes and host cell specificity makes 
them attractive candidates for vectors. Pathogenic factors can be replaced by genes whose 
products are of research interest or clinical benefit and the altered virus can be grown in a 
particular cell type.     
An area of research  exploiting these properties is ‘oncolytic virotherapy’, as a treatment for 
certain cancers, as highlighted by a recent paper 
1
 which was reported in the news.  Unlike  
‘phage therapy’, which uses viruses to destroy the antigenically ‘foreign’, pathogenic 
bacterial cells, virotherapy is used to target host cells – albeit those operating abnormally.    
The use of viruses to treat cancers does at first seem counterintuitive, since one study has 
estimated that over 16% of newly diagnosed cancers around the worlds are linked to 
infectious agents 
2 
. Actively replicating viruses alter the host cell’s metabolic state and 
eventually cause cell death. This can trigger an immune response which can facilitate tissue 
damage and associated pathological changes, which can lead to cancer; this is seen in chronic 
infection with Hepatitis B and Hepatitis C viruses 
3
. Some viruses are known to modify the 
immune response to their advantage; for example Epstein Barr virus (EBV) ‘hides’ in host B 
lymphocytes while inducing B cell proliferation 
3 
.   Where integration of the virus genome 
into that of the host cell occurs, this can lead to mutations associated with malignancy and 
this is also a potential consequence of EBV infection 
3
. Viruses are also associated with 
contributing to with the abnormal proliferation of host cells which leads to a tumour, 
although this is not always malignant. While some Human Papilloma virus (HPV) types, 
particularly 16 and 18 are implicated in cervical cancer, other HPVs cause benign growth of 
warts on hands or verrucae on feet 
3
.  However, during the 20
th
 century , it was noticed that 
natural infections with some viruses appeared to result in reduction of tumour growth 
4, 5
. 
Research in vitro suggested that this is due to their affinity for cancer cells, coupled with 
alterations in the metabolic mechanisms by which viral replication is usually supressed 
5,6 
. 
Some success has been shown in animal models and early clinical trials with attenuated 
versions of species which have this tendency to bind to tumour cells, including Mumps Virus, 
Measles Virus, as well as the animal pathogens Newcastle Disease Virus and Vesicular 
Stomatitis Virus 
 5,6 
. However, progress has been hampered by variable results and the fact 
that candidates identified to date are RNA viruses which are prone to mutation in vivo, which 
raises safety concerns 
5,6
. More success has been achieved with the targeted approach of 
specifically modifying the virus genome to remove pathogenic factors, make them able to 
replicate only in growing and dividing cells and also to have a tropism for a particular type of 
tumour marker 
5 , 6. 
Along with the more controlled targeted effect, virus activity should 
stimulate a localised immune response in the tumour region, thus contributing to its 
destruction and removal 
6,7
 Examples of selected key oncolytic virotherapy agents are 
discussed in detail by Davis and Fang 
5 
. A number of advantages and disadvantages of using 
these modified viruses are ant-cancer  therapy are given in Text box 1.  
 
 Text box 1: Advantages and Disadvantages of Oncolytic Virotherapy agents 
Advantages Disadvantages 
Therapeutic viral strains designed to 
specifically target abnormally operating 
tumour cells which express altered surface 
antigens  
Specific targeting requires modification of 
virus – attenuated strains may revert to wild 
type; deliberate deletion of genes may lead to 
loss of vital functions  
Deliberate alteration of virus genome allows 
inclusion of factors which enhance local 
immune response to tumour 
Lack of clear understanding of host cell – 
virus interaction may lead to unexpected  
affects on activity of products of inserted 
genes  
Oncolyotic virotherapy agents can be used in 
conjunction with more conventional cancer 
treatments including radio- and chemo-
therapy 
Safety concerns when using modified forms 
of viruses which naturally persist in the host, 
such as HSV  
 
 
  
To date, the best candidate therapies have been based on dsDNA viruses, most notably 
variants of Adenovirus type 5 and Herpes Simplex Virus  type 1 
5
. For example, ONYX-015 
is an adenovirus strain in which the gene coding for E1B protein has been deleted 
4,5
. This 
protein suppresses the activity of p53, which induces apoptosis in the host cell and stops the 
cell cycle when there is damage. Lack of a functioning p53 gene product is a feature of many 
tumours, including breast, bladder, ovarian and head and neck cancers, which means that  the 
ONYX-015 adenovirus does not need to counteract it to replicate inside these cells. Thus the 
idea is that it can replicate and lyse the cancerous cells while being inhibited in normal 
healthy cells 
5
 .  This mutant virus was developed in the late 1980s and in clinical trials it was 
used in conjunction with more conventional cancer treatments such as radiotherapy and 
chemotherapy, with some reported success. However, the issue of exactly how the selective 
toxicity works and doubts as to whether the lack of p53 in the tumour cells was in fact the 
key to the mechanism of action led to further development of the preparation being 
discontinued in the 2000s 
5
. Better progress was made with trials in China of another 
modified adenovirus, H101, used against head and neck cancers, along with anticancer drugs. 
This is now a licensed treatment in that country 
4
.  There are a number of other potential 
oncolytic virus treatments in development and the latest candidate is a modified version of 
Herpes Simplex Type 1 called Talimogene laherparepvec (T-VEC) 
1,7
. The gene for the viral 
neurovirulence factor ICP34.5 has been deleted, along with the ICP47 gene, whose product 
works to suppress antigen presentation of herpes infected cells 
1
 .  In addition, the gene for 
human granulocyte macrophage colony-stimulating factor ( GM-CSF) has been inserted into 
the genome, which is intended to promote antigen presentation and activate T cell responses 
to cancerous cells 
1 
.  
The paper  by Andtbacka et al 
1 
which was published recently, reports a phase III clinical trial 
of T-VEC  which was conducted between May 2009 and July 2011. Patients with melanoma 
at stages IIIB to IV which had been confirmed by histology and which was deemed not 
suitable for surgical resection were eligible for the study. Patients were recruited at 64 study 
centres across four countries ( UK, USA, Canada and South Africa) and in the end 418 
entered into the project. Around 2/3 of the patients (291) were assigned the T-VEC treatment, 
which was injected directly into the melanoma lesions, while the remaining 127 received a 
preparation containing only recombinant GM-CSF and this was given subcutaneously. The 
timings of the doses were slightly different for the two treatment regimens, but they were 
each conducted for a minimum of 24 weeks (at which point the lesion was assessed) and then 
continued for up to 12 months, as deemed necessary and in accordance with the patient’s 
wishes. The results showed that 78 of the patients given T-VEC had a clinically verified 
response within 12 months and which lasted for 6 months or longer. The median duration of 
treatment needed to achieve this response was 4.1 months. This compared to 8 patients 
showing a similar outcome from the GM-CSF treatment, although the median time to the 
response was 2.8 months 
1
. . The cancers were very advanced in these patients and other 
treatments had not been successful, so it is perhaps not surprising that for most of the 
patients, this therapy did not work. The median time to deciding that the regimen had failed 
was shorter for patients on GM-CSF than those on T-VEC (2.9 months and 8.2 months 
respectively). Similarly although the majority (290) of participants died, this figure 
comprised 65% of those on T-VEC and a median survival time of 23.3 months, in contrast to 
80% of those on GM-CSF, who survived for 18.9 months on average. This study showed that 
the oncolytic viral immunotherapy agent, T-VEC, could remove melanomas and slow the rate 
of the development of the disease. However at present it is clearly not a cure and perhaps 
trials involving patients at earlier stages of the cancer would be beneficial.  
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